# NEW POTENTIAL OF RHEUMATIC DISEASES IMMUNOBIOLOGICAL THERAPY 

Kirshenbaum E.V., Fomina G.P., Avidzba Y.N. The National University of Pharmacy, Kharkov, Ukraine klinlab@ukr.net

Chronic inflammation in rheumatoid arthritis (RA) and many other systemic diseases of connective tissue extend beyond the joints. Patients with RA have an increased risk of disease development in cardio-vascular system, lungs, eyes, musculoskeletal system. Effective control of inflammation becomes important and is the key to improving outcomes for patients with rapidly progressive RA. Traditional treatments are often ineffective for patients with RA, as they do not completely suppress the inflammation that causes its progression.

Thanks to the appearance of biological agents, especially inhibitors of tumor necrosis UPE-a, there were alternative effective means obtained, which are characterized by high efficiency and ensure rapid and sustained improvement.

The purpose of the research. To study the state of rheumatic diseases immunobiological treatment.

Materials and methods. We have researched the effectiveness of the drug "Rituximab" - Mab-Thera for patients with an inadequate response to the ongoing complex treatment in serum department 27 GKB Kharkov.

Obtained results. Mab-Thera application for 26 patients with RA is accompanied with clinical improvement of state of the disease with a marked reduction in the immune-inflammatory activity. Mab-Thera prescription for patients with systemic lupus erythematous with active lupus nephritis resistant to basic drugs leads to reduction of the nephritic syndrome and stabilization of the nephritis course. Mab-Thera prescription for patients with Sjogren's syndrome, accompanied by high activity, leads to improved clinical and laboratory parameters of the disease.

Summary. Thus, the use of new biological agents for the treatment of systemic connective tissue diseases can slow the progression of the disease, and also to achieve stable, long-term remission of it in most cases.

